文献速递白血病淋巴瘤

TP53 胚系变异影响儿童 B 细胞急性淋巴细胞白血病的易感性与预后

TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children.
PubMed 文献 · J Clin Oncol · 2018-01-04

在 3801 例儿童肿瘤协作组一线 ALL 临床试验患儿中行 TP53 编码区靶向测序,77 例(2.0%)检出 49 个独特非沉默罕见 TP53 编码变异,其中 22 个为致病性。TP53 致病性变异在 ALL 中显著富集(OR=5.2,P<.001),携带者诊断年龄更大(中位 15.5 岁 vs 7.3 岁,P<.001),更易为低二倍体 ALL(65.4% vs 1.2%,P<.001),无事件生存和总生存更差(HR 分别为 4.2 和 3.9),第二肿瘤 5 年累积发生率 25.1% vs 0.7%(P<.001)。

要点

  • 儿童 ALL 中 TP53 致病性胚系变异与 ALL 易感性及不良治疗结局相关。
  • 携带 TP53 致病性变异者诊断年龄更大、低二倍体 ALL 比例更高。
  • 携带者第二肿瘤 5 年累积发生率 25.1% vs 0.7%(P<.001)。

核心结论

  • 功能丧失性胚系 TP53 变异使儿童易患 ALL,并导致 ALL 治疗的不良结局,尤其是第二恶性肿瘤风险。

研究设计与样本

  • 对儿童肿瘤协作组一线 ALL 临床试验 AALL0232 和 P9900 中的 3801 例儿童行 TP53 编码区靶向测序。
  • 按实验测定的转录活性、计算机预测的有害效应及非 ALL 对照人群中的频率评估 TP53 变异致病性。
  • 分析 TP53 变异与 ALL 就诊特征及治疗结局的关联。

主要发现

  • 3801 例测序患儿中 77 例(2.0%)检出 49 个独特非沉默罕见 TP53 编码变异,其中 22 个分类为致病性。
  • TP53 致病性变异在 ALL 中较非 ALL 对照显著富集(OR=5.2,P<.001)。
  • 携带 TP53 致病性变异者诊断 ALL 时年龄显著更大(中位 15.5 岁 vs 7.3 岁,P<.001),更易为低二倍体 ALL(65.4% vs 1.2%,P<.001)。
  • 携带胚系 TP53 致病性变异与较差的无事件生存和总生存相关(HR 分别为 4.2 和 3.9,P<.001 和 .001)。
  • 携带 TP53 致病性变异者第二肿瘤风险显著更高,5 年累积发生率 25.1% vs 0.7%(P<.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Germline TP53 variation is the genetic basis of Li-Fraumeni syndrome, a highly penetrant cancer predisposition condition. Recent reports of germline TP53 variants in childhood hypodiploid acute lymphoblastic leukemia (ALL) suggest that this type of leukemia is another manifestation of Li-Fraumeni syndrome; however, the pattern, prevalence, and clinical relevance of TP53 variants in childhood ALL remain unknown. Patients and Methods Targeted sequencing of TP53 coding regions was performed in 3,801 children from the Children's Oncology Group frontline ALL clinical trials, AALL0232 and P9900. TP53 variant pathogenicity was evaluated according to experimentally determined transcriptional activity, in silico prediction of damaging effects, and prevalence in non-ALL control populations. TP53 variants were analyzed for their association with ALL presenting features and treatment outcomes. Results We identified 49 unique nonsilent rare TP53 coding variants in 77 (2.0%) of 3,801 patients sequenced, of which 22 variants were classified as pathogenic. TP53 pathogenic variants were significantly over-represented in ALL compared with non-ALL controls (odds ratio, 5.2; P < .001). Children with TP53 pathogenic variants were significantly older at ALL diagnosis (median age, 15.5 years v 7.3 years; P < .001) and were more likely to have hypodiploid ALL (65.4% v 1.2%; P < .001). Carrying germline TP53 pathogenic variants was associated with inferior event-free survival and overall survival (hazard ratio, 4.2 and 3.9; P < .001 and .001, respectively). In particular, children with TP53 pathogenic variants were at a dramatically higher risk of second cancers than those without pathogenic variants, with 5-year cumulative incidence of 25.1% and 0.7% ( P < .001), respectively. Conclusion Loss-of-function germline TP53 variants predispose children to ALL and to adverse treatment outcomes with ALL therapy, particularly the risk of second malignant neoplasms.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Qian M, Cao X, Devidas M, et al. TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. J Clin Oncol. 2018. PMID: 29300620. doi:10.1200/JCO.2017.75.5215

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。